| Quote
: |
符超君,凌艳君,颜家朝,赵洪庆,秦裕辉.双丹明目胶囊对糖尿病视网膜病变大鼠视网膜Ras-Raf-1-MEK-ERK通路的调控作用[J].湖南中医药大学学报英文版,2018,38(7):728-731.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 1799times Download 480times |
| 双丹明目胶囊对糖尿病视网膜病变大鼠视网膜Ras-Raf-1-MEK-ERK通路的调控作用 |
| 符超君,凌艳君,颜家朝,赵洪庆,秦裕辉 |
| (湖南中医药大学, 湖南 长沙 410208;湖南省中医药研究院, 湖南 长沙 410006) |
| 摘要: |
| 目的 观察双丹明目胶囊对糖尿病视网膜病变（diabetic retinopathy，DR）大鼠视网膜组织Ras-Raf-1-MEK-ERK通路的调控作用，探讨其可能的作用机制。方法 取60只SD大鼠首先随机分为2组，即正常组（A组，10只）和糖尿病组（50只），将50只糖尿病组大鼠经一次性尾静脉注射STZ（50 mg/kg）诱导糖尿病模型，通过眼底荧光血管造影确诊DR模型后，选取其中45只大鼠再随机分为模型组（B组）、阳性药物组（C组）、双丹明目胶囊高剂量组（D组）、双丹明目胶囊中剂量组（E组）、双丹明目胶囊低剂量组（F组），每组9只。所有大鼠均干预30 d，末次给药后，检测所有大鼠空腹血糖值，Western-blot法和RT-PCR法分别检测大鼠视网膜Ras、Raf-1、MEK、ERK蛋白和基因的表达。结果 与A组比较，B组大鼠血糖显著升高，视网膜Ras、Raf-1、MEK、ERK蛋白和基因表达均显著上升（P<0.01）；双丹明目胶囊干预后，与B组比较，D组大鼠血糖值下降，视网膜Ras、Raf-1、MEK、ERK蛋白和基因表达均降低（P<0.05或P<0.01）；同时，E组也能使视网膜Ras、Raf-1、ERK蛋白表达降低、Raf-1、ERK基因表达降低（P<0.05）。结论 双丹明目胶囊能通过调控Ras-Raf-1-MEK-ERK通路而发挥治疗DR的作用。 |
| 关键词: 双丹明目胶囊 糖尿病视网膜病变 Ras-Raf-1-MEK-ERK |
| DOI：10.3969/j.issn.1674-070X.2018.07.003 |
| Received:March 12, 2018 |
| 基金项目:国家自然科学基金面上项目（81473737）。 |
|
| Effect of Shuangdan Mingmu Capsule on the Ras-Raf-1-MEK-ERK Pathway in Retinal Tissue in Rats with Diabetic Retinopathy |
| FU Chaojun,LING Yanjun,YAN Jiachao,ZHAO Hongqing,QIN Yuhui |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Hunan Academy of Chinese Medicine, Changsha, Hunan 410006, China) |
| Abstract: |
| Objective To observe the regulatory effect of Shuangdan Mingmu Capsule on the Ras-Raf-1-MEK-ERK pathway in retinal tissue in rats with diabetic retinopathy (DR), and to investigate its possible mechanism of action. Methods Sixty Sprague-Dawley rats were randomly divided into two groups:normal control group (group A, 10 rats) and diabetic group (50 rats). The rats in the diabetic group were given a single tail vein injection of STZ (50 mg/kg) to establish a DR model, which was confirmed by fundus fluorescein angiography, and then 45 rats were randomly selected and divided into model group (group B), positive drug group (group C), and high-, medium-, and low-dose Shuangdan Mingmu Capsule groups (groups D, E, and F), with 9 rats in each group. All rats were treated for 30 days. After the last administration, fasting blood glucose was measured in all rats. The mRNA and protein expression of Ras, Raf-1, MEK, and ERK was determined by RT-PCR and Western blot, respectively. Results Compared with group A, group B showed significant increases in fasting blood glucose and the mRNA and protein expression of Ras, Raf-1, MEK, and ERK in the retina (P<0.01). Compared with group B, group D showed significant reductions in fasting blood glucose and the mRNA and protein expression of Ras, Raf-1, MEK, and ERK in the retina (P<0.05 or P<0.01), and group E showed significant reductions in the protein expression of Ras, Raf-1, and ERK in the retina as well as the mRNA expression of Raf-1 and ERK (P<0.05). Conclusion Shuangdan Mingmu Capsule can play a role in the treatment of DR by regulating the Ras-Raf-1-MEK-ERK pathway. |
| Key words: Shuangdan Mingmu Capsule diabetic retinopathy Ras-Raf-1-MEK-ERK |
|
二维码（扫一下试试看！） |
|
|
|
|
